论文部分内容阅读
目的:观察胸腺肽联合利巴韦林治疗手足口病的疗效。方法:53例手足口病患儿分成2组,治疗组33例,应用胸腺肽联合利巴韦林治疗;对照组20例,单用利巴韦林治疗。结果:治疗组总有效率96.9%,高于对照组的75.0%(P<0.05)。治疗组发热、皮疹及口腔疱疹消退时间,以及治疗后IgG等指标,均优于对照组(P<0.01或0.05),两组均未见明显不良反应。结论:胸腺肽联合利巴韦林治疗手足口病疗效较好。
Objective: To observe the efficacy of thymosin combined with ribavirin in the treatment of hand, foot and mouth disease. Methods: 53 children with HFMD were divided into two groups. The treatment group consisted of 33 patients treated with thymosin and ribavirin. The control group received 20 patients treated with ribavirin alone. Results: The total effective rate in the treatment group was 96.9%, which was higher than that in the control group (75.0%, P <0.05). The treatment group fever, rash and oral herpes subsided time, and IgG and other indicators after treatment were better than the control group (P <0.01 or 0.05), no significant adverse reactions in both groups. Conclusion: Thymosin combined with ribavirin treatment of hand, foot and mouth disease is better.